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The UK Standardisation of Breast Radiotherapy (START) 
Trial B of radiotherapy hypofractionation for treatment of 
early breast cancer: a randomised trial
The START Trialists’ Group*
Summary
Background The international standard radiotherapy schedule for early breast cancer delivers 50 Gy in 25 fractions of 
2·0 Gy over 5 weeks, but there is a long history of non-standard regimens delivering a lower total dose using fewer, 
larger fractions (hypofractionation). We aimed to test the beneﬁ ts of radiotherapy schedules using fraction sizes 
larger than 2·0 Gy in terms of local-regional tumour control, normal tissue responses, quality of life, and economic 
consequences in women prescribed post-operative radiotherapy.
Methods Between 1999 and 2001, 2215 women with early breast cancer (pT1-3a pN0-1 M0) at 23 centres in the UK 
were randomly assigned after primary surgery to receive 50 Gy in 25 fractions of 2·0 Gy over 5 weeks or 40 Gy in 
15 fractions of 2·67 Gy over 3 weeks. Women were eligible for the trial if they were aged over 18 years, did not have 
an immediate reconstruction, and were available for follow-up. Randomisation method was computer generated 
and was not blinded. The protocol-speciﬁ ed principal endpoints were local-regional tumour relapse, deﬁ ned as 
reappearance of cancer at irradiated sites, late normal tissue eﬀ ects, and quality of life. Analysis was by intention 
to treat. This study is registered as an International Standard Randomised Controlled Trial, number 
ISRCTN59368779.
Findings 1105 women were assigned to the 50 Gy group and 1110 to the 40 Gy group. After a median follow up of 
6·0 years (IQR 5·0–6·2) the rate of local-regional tumour relapse at 5 years was 2·2% (95% CI 1·3–3·1) in the 40 Gy 
group and 3·3% (95% CI 2·2 to 4·5) in the 50 Gy group, representing an absolute diﬀ erence of –0·7% (95% CI 
–1·7% to 0·9%)—ie, the absolute diﬀ erence in local-regional relapse could be up to 1·7% better and at most 1% worse 
after 40 Gy than after 50 Gy. Photographic and patient self-assessments indicated lower rates of late adverse eﬀ ects 
after 40 Gy than after 50 Gy.
Interpretation A radiation schedule delivering 40 Gy in 15 fractions seems to oﬀ er rates of local-regional tumour 
relapse and late adverse eﬀ ects at least as favourable as the standard schedule of 50 Gy in 25 fractions.
Introduction
The international standard radiotherapy regimen after 
breast conservation surgery or mastectomy for early breast 
cancer delivers 25 daily doses (fractions) of 2·0 Gy to a 
total dose of 50 Gy over 5 weeks.1–4 Alternative schedules 
based on a lower total dose delivered in fewer, larger 
fractions (hypofractionation) were introduced in the UK 
and Canada several decades ago5 on an empirical basis, 
and 40 Gy in 15 fractions over 3 weeks is a commonly used 
regimen.5,6 Results of retrospective studies of 
hypofractionated radiotherapy in early breast cancer 
suggest satisfactory outcomes in terms of tumour control 
and late adverse eﬀ ects if modest increases in fraction size 
are combined with appropriate downward adjustments to 
total dose.7–14 The ﬁ rst results of a Canadian randomised 
trial testing 42·5 Gy in 16 fractions against 50 Gy in 
25 fractions are consistent with these ﬁ ndings, suggesting 
equivalence in terms of local control and breast cosmesis 
for the 16-fraction regimen.15
Fractions of more than 2·0 Gy caused unacceptable 
rates of late adverse eﬀ ects when inadequate downward 
adjustments to total dose were applied several decades 
ago.16–20 Despite widespread empirical use in the UK, 
40 Gy in 15 fractions has never been formally compared 
with standard fractionation, raising concerns in the 
mid-1990s that it could be less eﬀ ective or less safe than 
50 Gy in 25 fractions. To address this uncertainty, the 
Standardisation of Breast Radiotherapy (START) Trials 
were initiated by the then UK Coordinating Committee 
for Cancer Research (now National Cancer Research 
Institute) to test the eﬀ ects of radiotherapy schedules 
using fraction sizes larger than 2·0 Gy. START Trial A21 
tested two dose levels of a 13-fraction regimen delivered 
over 5 weeks in order to measure the sensitivity of 
normal and malignant tissues to fraction size. START 
Trial B compared 40 Gy in 15 fractions of 2·67 Gy in 
3 weeks with a control group of 50 Gy in 25 fractions of 
2·0 Gy over 5 weeks. This paper presents the results of 
Trial B.
Methods
Participation was open to all UK centres that provided 
radiotherapy treatment to patients with early breast 
cancer. With START Trials A and B running in parallel, 
centres chose to participate in either Trial A (17 centres) 
or B (23 centres).
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Patients
Women with operable invasive breast cancer 
(International Union Against Cancer stage pT1-3a pN0-1 
M0) requiring radiotherapy after primary surgery (breast 
conserving surgery or mastectomy, with clear tumour 
margins ≥1 mm) were eligible for the trial if they were 
aged over 18 years, did not have an immediate 
reconstruction, and were available for follow-up. Patients 
from 21 of the centres participating in Trial B were also 
recruited into the quality of life and health economics 
studies (health economics data not presented here, 
baseline quality of life data have been published 
elsewhere22). 20 of the centres participating in the quality 
of life study recruited patients with breast conserving 
surgery into the photographic assessment of Trial B. 
Patients from 17 centres also consented to donate a 20 mL 
blood sample and to complete an associated family 
history questionnaire (substudy not reported here). The 
START Trials were approved by the South Thames 
Multi-Research Ethics Committee in September, 1998, 
and by the local ethics committees of all participating 
centres. Written informed consent was obtained for all 
patients.
Procedures
START Trial B patients were randomised to 50 Gy in 
25 fractions over 5 weeks or to 40 Gy in 15 fractions over 
3 weeks. Randomisation was arranged via telephone at 
the Clinical Trials and Statistics Unit at the Institute of 
Cancer Research (ICR-CTSU), Sutton, UK, where patient 
details were recorded and treatment was allocated. 
Randomisation was not blinded. Computer-generated 
random permuted blocks were used as the method of 
allocation, with patients stratiﬁ ed by hospital, type of 
surgery (breast conserving surgery or mastectomy), and 
intention to give a tumour bed boost dose or not. Use of 
adjuvant systemic treatment was recorded, with a 
requirement of at least a 2-week gap between exposure to 
chemotherapy and radiotherapy.
Patients lay in a supine treatment position. The 
planning target volume was deﬁ ned as the whole breast 
with a 1 cm margin to palpable breast tissue; where 
regional radiotherapy was indicated, the planning target 
volume was supraclavicular nodes with or without axillary 
chain with a 1 cm margin. Most patients were treated 
with 6 MV x-rays, although treatment with higher 
energies or cobalt γ-rays was allowed after discussion 
with the START Trial radiotherapy quality assurance 
team. Planning protocols were speciﬁ ed at the time of 
notiﬁ cation of participation into the study and had to 
conform to the minimum quality criteria described in 
the protocol. Planning protocols varied slightly between 
centres, but within each centre they were identical in 
each fractionation group. Doses were prescribed to 
international reference points.23 Departments were 
required to have a protocol specifying whether patients 
who had had breast conserving surgery would receive a 
boost to the tumour bed, and to use an electron ﬁ eld of 
appropriate energy to deliver 10 Gy in ﬁ ve daily fractions 
to the 100% isodose, after initial radiotherapy.
All centres submitted details of the standard 
radiotherapy technique, after which a visit by the quality 
assurance team checked dosimetric measurements in a 
2D and 3D breast phantom, including the junction region 
between supraclavicular fossa and tangential breast or 
chest wall ﬁ elds.24–27 The mean diﬀ erence between 
prescribed and measured dose in a phantom was 2·1%. 
Additionally, a third of the radiotherapy treatment plans 
were collected and analysed by the quality assurance 
team to ensure compliance with the protocol in terms of 
prescription point, dose homogeneity, and lung depth, 
and a random sample of patients had in-vivo 
thermoluminescent dosimeter measurements done.28–30 
The protocol allowed for a dose variation (in the planning 
target volume) between 95% and 105% of that at the 
reference point on the central axis. Lung depth data was 
obtained by the radiotherapy quality assurance 
programme, and analysis indicated that most patients 
had less than 2 cm of lung within the treatment volume. 
These results conﬁ rmed a good compliance with the 
technical aspects of the trial protocol.
The principal endpoints speciﬁ ed in the protocol were 
local-regional relapse, normal tissue eﬀ ects, and quality 
of life. Local-regional tumour relapse was deﬁ ned as local 
2215 patients randomised
1105 allocated 50 Gy in 25 fractions
           over 5 weeks
1110 allocated 40 Gy in 15 fractions
           over 3 weeks
1091 received allocated treatment*
        6 treatment stopped early
        5 refused allocated treatment
        1 opted for mastectomy (no
           radiotherapy given)
        1 had chicken pox after 4 fractions
           so treatment delayed (56 Gy
           given in total)
        1 second primary in lung, so no
           breast radiotherapy given
1103 received allocated treatment*
       4 given non-allocated treatment
        1 refused allocated treatment
        1 had subarachnoid haemorrhage
            so treatment abandoned after 
            1 fraction   
        1 breast lump was found to be
            secondary to bowel cancer
10 with baseline data only
       7 withdrew consent to
          follow-up after randomisation
       3 ineligible
9 with baseline data only
    5 withdrew consent to
       follow-up after randomisation
    2 moved
    2 unknown
1105 included in analysis 1110 included in analysis
Figure 1: Trial proﬁ le for START Trial B
*Only major treatment deviations listed. Minor deviations due to public holidays, machine service days, and 
machine breakdowns not included.
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relapse in breast or chest wall, and regional relapse in 
ipsilateral axilla or supraclavicular fossa if it had been 
within an irradiated target volume. Any ipsilateral 
regional relapse outside the radiotherapy target volume 
was excluded from the analysis of local-regional relapse. 
Normal tissue eﬀ ects in the breast, arm, and shoulder 
were assessed by photographic comparison with baseline, 
patient self-reported assessments, and physician 
assessments. Other endpoints were disease-free and 
overall survival, second primary cancers, and health 
economic consequences. Disease-free survival was 
deﬁ ned as time to any breast cancer-related event 
(local-regional or distant relapse, contralateral breast 
cancer, or death from breast cancer). Data relating to ﬁ ve 
key breast normal tissue eﬀ ects from the patient quality 
of life self-assessments are presented here. Separate 
papers will present the full analysis of all self-assessments 
and physician assessments of normal tissue eﬀ ects, and 
of quality of life. Cases of ischaemic heart disease, 
symptomatic rib fracture, and symptomatic lung ﬁ brosis 
were recorded during follow-up; incidence with and 
without conﬁ rmation of diagnosis (eg, using imaging 
and further investigation) was included. Brachial 
plexopathy was reported if damage to the brachial plexus 
was suspected and the patient had symptoms of pain, 
parasthesia, numbness, or other sensory symptoms 
(graded on a 4-point scale). Suspected cases of brachial 
plexopathy were subject to conﬁ rmation by 
neurophysiological assessment and MRI.
Patients were reviewed every year for tumour relapse 
and radiotherapy-induced normal tissue eﬀ ects. Clinical 
data were recorded on pre-printed case report forms and 
sent to the coordinating clinical trials oﬃ  ce at the 
ICR-CTSU, Sutton, UK. Photographs were taken at 
baseline (post-surgery and pre-radiotherapy) and then 
at 2 and 5 years to assess changes to the breast based on 
change in size, shrinkage, and shape, and scored on a 
3-point graded scale. Changes in breast appearance 
(photographic) were scored by three observers blind to 
patient identity, treatment allocation, and year of follow-up, 
and a ﬁ nal agreed score reached by consensus. Breast size 
and surgical deﬁ cit were both deﬁ ned from the baseline 
photographs by the same three observers applying 3-point 
graded scales. Quality of life data were obtained using 
standardised questionnaires31–34 at baseline and at 
6 months, 1, 2, and 5 years. Post-baseline quality of life 
ques tionnaires included an additional four protocol-
speciﬁ c items relating to changes in the aﬀ ected breast 
after radiotherapy (skin changes in the area of the aﬀ ected 
breast, overall change in breast appearance, ﬁ rmness to 
touch of the aﬀ ected breast, and reduction in size of the 
aﬀ ected breast). Of these four items, patients who had had 
mastectomy only rated change in skin appearance after 
radiotherapy. Details of the quality of life study protocol 
and baseline data have been published elsewhere.22
The trial was coordinated by the ICR-CTSU, Sutton, UK. 
The trial was overseen by a Steering Committee of several 
independent experts joined by members of the ICR-CTSU, 
START Trial Management Group, and representatives of 
the funding bodies (as observers). The Trial Management 
Group was responsible for the day-to-day management of 
the trial, and the emerging safety and eﬃ  cacy data was 
reviewed regularly by the Independent Data Monitoring 
Committee. Central statistical monitoring of data was 
done by ICR-CTSU, supplemented by selected on-site 
source document veriﬁ cation.
Statistical analysis
A 5-year local-regional tumour relapse rate of 10% in 
the 50 Gy group was predicted, based on the earlier 
Fractionation schedule Total n=2215
50 Gy in 25 fractions 
n=1105
40 Gy in 15 fractions 
n=1110
Age (years)
20–29 7 (0·6) 0 (0·0) 7 (0·3)
30–39 62 (5·6) 39 (3·5) 101 (4·6)
40–49 179 (16·2) 170 (15·3) 349 (15·8)
50–59 427 (38·6) 447 (40·3) 874 (39·5)
60–69 304 (27·5) 327 (29·5) 631 (28·5)
70–79 117 (10·6) 119 (10·7) 236 (10·7)
80– 9 (0·8) 8 (0·7) 17 (0·8)
Mean (SD) 57·0 (10·4) 57·8 (9·5) 57·4 (10·0)
Time from surgery to randomisation 
(weeks); median (IQR) [range]
7·3 (4·9–12·3)
[0·9–45·3]
7·1 (4·9–11·9)
[0·6–49·3]
7·3 (4·9–12·0)
[0·6–49·3]
Primary surgery
Breast conserving surgery 1020 (92·3) 1018 (91·7) 2038 (92·0)
Mastectomy 85 (7·7) 92 (8·3) 177 (8·0)
Histological type
Invasive ductal 865 (78·3) 843 (75·9) 1708 (77·1)
Invasive lobular 122 (11·0) 132 (11·9) 254 (11·5)
Mixed ductal/lobular 20 (1·8) 25 (2·3) 45 (2·0)
Other 95 (8·6) 103 (9·3) 198 (8·9)
Not known 3 (0·3) 7 (0·6) 10 (0·5)
Pathological node status
Positive 238 (21·5) 266 (24·0) 504 (22·8)
Negative 831 (75·2) 804 (72·4) 1635 (73·8)
Not known (no axillary surgery) 36 (3·3) 39 (3·5) 75 (3·4)
Not known (missing data) 0 (0·0) 1 (0·1) 1 (0·04)
Tumour size (cm)
<1 151 (13·7) 167 (15·0) 318 (14·4)
1– 552 (50·0) 542 (48·8) 1094 (49·4)
2– 287 (26·0) 288 (25·9) 575 (26·0)
3– 113 (10·2) 107 (9·6) 220 (9·9)
Not known 2 (0·2) 6 (0·5) 8 (0·4)
Tumour grade
1 306 (27·7) 311 (28·0) 617 (27·9)
2 518 (46·9) 532 (47·9) 1050 (47·4)
3 261 (23·6) 248 (22·3) 509 (23·0)
Not known (not applicable)* 15 (1·4) 15 (1·3) 30 (1·3)
Not known 5 (0·4) 4 (0·4) 9 (0·4)
(Continues on next page)
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Royal Marsden Hospital/Gloucestershire Oncology 
Centre (RMH/GOC) pilot trial.35 A target sample size of 
1840 patients was deﬁ ned in Trial B to provide 
95% power to exclude an increase of 5% in the 
local-regional relapse rate for the 40 Gy group compared 
with 50 Gy (one-sided α=0·025). The protocol speciﬁ ed 
that if the true 5-year local-regional relapse rate in the 
50 Gy group was lower than expected (eg, 5%), this 
sample size would give more than 95% power to detect 
an increase of 5% in the local-regional relapse rate in 
the 40 Gy group.
Survival analysis methods were used to compare rates 
of each endpoint between the fractionation schedules. 
Length of follow-up was calculated as time from 
randomisation until time of ﬁ rst event or last follow-up 
assessment, whichever occurred ﬁ rst. Patients were still 
evaluable for local-regional relapse after distant relapse, 
but were censored at date of death. For the photographic 
endpoint, patients were no longer evaluable for change 
in breast appearance after local-regional relapse. 
Kaplan-Meier estimates of 5-year relapse rates, rates of 
normal tissue eﬀ ects, rates of any breast-cancer related 
event, and mortality rates were calculated (with 95% CIs). 
For the patient quality of life self-assessments of normal 
tissue eﬀ ects an event was deﬁ ned as the ﬁ rst occurrence 
of a moderate or marked symptom (graded “quite a bit” 
or “very much”). The scores from the photographic 
assessments of change in breast appearance at 2 and 
5 years were dichotomised as none versus mild or marked 
change, and the ﬁ rst occurrence of such a change was 
taken as the endpoint for the survival analysis. There 
were too few patients with marked change in breast 
appearance to be able to analyse this category separately. 
The log-rank test was used to compare fractionation 
schedules. Crude hazard ratios (with 95% CIs) comparing 
fractionation schedules for each endpoint were obtained 
from Cox proportional hazards regression models. The 
proportionality assumption of the Cox model was tested 
using Schoenfeld residuals and was found to be valid for 
all of the analyses. Since point estimates of diﬀ erences in 
event rates can, by chance, be atypical of the overall 
pattern of diﬀ erences between schedules, estimates of 
the absolute diﬀ erence in 5-year event rates taking the 
whole range of observation times into account were 
obtained by applying the hazard ratios obtained from the 
Cox model to the Kaplan-Meier estimate of the rate in the 
50 Gy control group.36 Both one-sided and two-sided 
95% CIs were calculated for the absolute diﬀ erence in 
local-regional relapse rates at 5 years, since the upper 
limit is of greater clinical interest, in view of concern 
about a possible excess risk caused by hypofractionated 
schedules. Kaplan-Meier survival curves and Nelson-Aalen 
cumulative hazard functions were plotted according to 
fractionation schedule. Plots were censored at the median 
length of follow-up (rounded to nearest year).
Analysis included all randomised patients on an 
intention-to-treat basis. This study is registered as an 
International Standard Randomised Controlled Trial, 
number ISRCTN59368779.
Role of the funding source
The funding sources provided peer-reviewed approval for 
the trial and have had representation (as observers) on 
the Trial Steering Committee, but had no other role in 
the design, conduct, data collection, data analysis or 
interpretation of the study or the results. The 
corresponding author had full access to all the data in the 
study, and had ﬁ nal responsibility for the decision to 
submit for publication.
Results
Between January, 1999, and October, 2001, 2215 patients 
were enrolled in START Trial B at 23 centres in the UK 
(ﬁ gure 1). A total of 1079 patients were enrolled in the 
quality of life study and 1094 in the photographic 
assessment study (with 930 patients enrolled in both 
substudies).
Fractionation schedule Total n=2215
50 Gy in 25 fractions 
n=1105
40 Gy in 15 fractions 
n=1110
(Continued from previous page)
Adjuvant therapy
None 37 (3·3) 47 (4·2) 84 (3·8)
Tamoxifen/no chemotherapy 782 (70·8) 810 (73·0) 1592 (71·9)
Chemotherapy/no tamoxifen 77 (7·0) 78 (7·0) 155 (7·0)
Tamoxifen+chemotherapy 181 (16·4) 155 (14·0) 336 (15·2)
Other endocrine therapy† 16 (1·4) 11 (1·0) 27 (1·2)
Not known 12 (1·1) 9 (0·8) 21 (0·9)
Lymphatic treatment
None 32 (2·9) 36 ( 3·2) 68 (3·1)
Surgery/no radiotherapy 980 (88·7) 984 (88·6) 1964 (88·7)
Radiotherapy/no surgery 5 (0·4) 3 (0·3) 8 (0·4)
Surgery+radiotherapy 74 (6·7) 79 (7·1) 153 (6·9)
Not known 14 (1·3) 8 (0·7) 22 (1·0)
Boost (BCS patients only) n=1020 n=1018 n=2038
Yes 422 (41·4) 446 (43·8) 868 (42·6)
No 584 (57·3) 565 (55·5) 1149 (56·4)
Not known 14 (1·4) 7 (0·7) 21 (1·0)
From baseline photographs n=522 (%) n=514 (%) n=1036 (%)
Breast size
Small 49 (9·4) 42 (8·2) 91 (8·8)
Medium 377 (72·2) 390 (75·9) 767 (74·0)
Large 96 (18·4) 82 (16·0) 178 (17·2)
Surgical deﬁ cit
Small 307 (58·8) 286 (55·6) 593 (57·2)
Medium 164 (31·4) 177 (34·4) 341 (32·9)
Large 51 (9·8) 51 (9·9) 102 (9·8)
Data are n (%) unless otherwise stated. BCS=breast conserving surgery. *Lobular and other histological types. †Other 
endocrine therapies include combinations of tamoxifen/anastrozole/letrozole/goserelin mostly within randomised trials.
Table 1: Demographic and clinical characteristics at randomisation of the 2215 patients in START Trial B
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Demographic and clinical characteristics were well 
balanced between the treatment groups (table 1). Of the 
women prescribed chemotherapy, 59·1% (290/491) 
received an anthracycline-containing regimen, which was 
balanced between randomised radiotherapy schedules 
(154/258 [59·7%] for 50 Gy and 136/233 [58·4%] for 40 Gy). 
Cyclophosphamide, methotrexate, and ﬂ uorouracil com-
bination therapy alone was prescribed in 196 women 
(39·9% of those receiving chemotherapy), which was 
similarly balanced between randomised groups 
(103 [39·9%] for 50 Gy and 93 [39·9%] for 40 Gy). Nine 
women (three allocated 50 Gy and six allocated 40 Gy) 
received an adjuvant taxane. Of the 1955 women prescribed 
tamoxifen or another endocrine therapy, almost all were 
continuing treatment at randomisation (956/979 [97·6%] 
for 50 Gy and 963/976 [98·7%] for 40 Gy). The quality of 
life subgroup included 12·3% women who had undergone 
mastectomy. There were only 21 major treatment deviations 
(including early stopping of treatment, patient refusal of 
allocated treatment, and patients found to be ineligible for 
reasons including presence of second primaries), resulting 
in 99·0% compliance with allocated treatment (ﬁ gure 1). 
Compliance with completion of quality of life 
questionnaires over 5 years was more than 90%.
Median follow-up of surviving patients was 6·0 years 
(IQR 5·0 to 6·2), with a maximum follow-up of 8·0 years. 
At the time of analysis, 1872 patients (84·5%) were alive 
and without relapse, 34 (1·5%) were alive with 
local-regional relapse (without distant relapse), 
45 (2·0%) were alive with distant relapse (including 
four with local-regional relapse), 245 (11·1%) had died 
(including 27 with local-regional relapse), and 
19 (0·9%) had no follow-up (ﬁ gure 1).
At the time of analysis, 65 (2·9%) patients had 
experienced a local-regional relapse. The hazard ratio 
for local-regional relapse after 40 Gy compared with 
50 Gy was 0·79 (95% CI 0·48–1·29; table 2). The 
estimated absolute diﬀ erence in local-regional relapse 
rates for 40 Gy compared with 50 Gy at 5 years 
was –0·7% (–1·7% to 0·9%), which indicates that the 
absolute diﬀ erence between schedules is likely to be at 
worst 0·9% higher and at best 1·7% lower after 40 Gy in 
15 fractions than after 50 Gy in 25 fractions. Since the 
main concern over hypofractionation is an excess risk 
rather than a possible beneﬁ t, a more precise estimate 
of the potential excess risk of local-regional relapse is 
obtained from the upper limit of the one-sided 95% CI 
for the absolute diﬀ erence in 5-year local-regional 
relapse rates. This calculation indicated an upper limit 
of 0·6% excess risk associated with the 15-fraction 
schedule. The Kaplan-Meier and cumulative hazard 
rate plots for local-regional relapse according to 
fractionation schedule (ﬁ gure 2) illustrate the low event 
rate in both randomised groups.
The 5-year rate of distant relapse was lower in the 40 Gy 
group (hazard ratio 0·69, 95% CI 0·53–0·91), which 
contributed to the higher rates of disease-free survival 
and overall survival than in the 50 Gy group (table 2). 
Analysis of the Kaplan-Meier and cumulative hazard rate 
plots indicated that the divergence in distant relapse 
Events/total (%) Estimated % with event 
by 5 years (95% CI)
Crude hazard ratio 
(95% CI)
Log-rank 
test p value
Local relapse*
50 Gy 34/1105 (3·1) 3·3 (2·2–4·4) 1
40 Gy 25/1110 (2·2) 2·0 (1·1–2·8) 0·72 (0·43–1·21) 0·21
Local-regional relapse
50 Gy 36/1105 (3·2) 3·3 (2·2–4·5) 1
40 Gy 29/1110 (2·6) 2·2 (1·3–3·1) 0·79 (0·48–1·29) 0·35
Distant relapse
50 Gy 122/1105 (11·0) 10·2 (8·4–12·1) 1
40 Gy 87/1110 (7·8) 7·6 (6·0–9·2) 0·69 (0·53–0·91) 0·01
Any breast cancer-related event†
50 Gy 164/1105 (14·8) 14·1 (12·0–16·2) 1
40 Gy 127/1110 (11·4) 10·6 (8·7–12·4) 0·75 (0·60–0·95) 0·02
All-cause mortality
50 Gy 138/1105 (12·5) 11·0 (9·1–12·9) 1
40 Gy 107/1110 (9·6) 8·0 (6·4–9·7) 0·76 (0·59–0·98) 0·03
*Local relapse deﬁ ned as ipsilateral local tumour relapse in breast parenchyma/breast skin/chest wall skin. †Local, 
regional, or distant relapse, breast cancer death, contralateral breast cancer (“disease-free survival”).
Table 2: Survival analyses of relapse and mortality according to fractionation schedule
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Figure 2: Kaplan-Meier plot (A) and Nelson-Aalen cumulative hazard plot (B) of local-regional tumour relapse 
in 2215 patients
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between the schedules began at around 1 year after 
randomisation (ﬁ gure 3).
Change in breast appearance (photographic) was 
assessed on a 3-point graded scale (none, mild, marked) 
in 923 patients with a baseline and at least one follow-up 
image (461 for 50 Gy and 462 for 40 Gy). Not all patients 
had photographs available at both 2 and 5 years, for 
reasons including the 5-year assessment not yet being 
done at the time of scoring and analysis, patient refusal, 
and withdrawal from the photographic study due to 
relapse. There were no associations between score for 
change in breast appearance (photographic) at 2 years or 
patient demographic or treatment characteristics and 
whether or not the patient had a 5-year assessment (data 
not shown). Mild change was graded for 284 
(30·8%) patients and marked change for 28 
(3·0%) patients, by 5 years. Change in breast appearance 
(photographic) was less likely after 40 Gy than after 50 Gy, 
with a hazard ratio of 0·83 (95% CI 0·66–1·04, p=0·06; 
ﬁ gures 4 and 5). Adjusting for breast size and surgical 
deﬁ cit made little diﬀ erence to these results. Figure 4 
shows that the treatment diﬀ erences were evident at the 
ﬁ rst time point of 2 years, and persisted to 5 years.
Patient quality of life self-assessments of normal tissue 
eﬀ ects were available for 1037 (96·1% of all patients 
in the quality of life study) patients with baseline infor-
mation and at least one completed follow-up questionnaire 
(511 for 50 Gy and 526 for 40 Gy). Changes in breast 
appearance and breast hardness (patients with breast-
conserving surgery) were the most common changes 
recorded. Analysis of patient self-assessments of ﬁ ve key 
normal tissue eﬀ ects on the breast and breast area 
showed that rates of moderate or marked eﬀ ects by 
5 years tended to be lower after 40 Gy than after 50 Gy, 
with a signiﬁ cantly lower rate of change in skin 
appearance after radiotherapy for 40 Gy than after 50 Gy 
(p=0·02; ﬁ gure 5). The results of the various assess-
ments of normal tissue eﬀ ects were consistently in favour 
of the 40 Gy group compared with 50 Gy (ﬁ gure  5).
The incidence of ischaemic heart disease, symptomatic 
rib fracture, and symptomatic lung ﬁ brosis was low at 
this stage during follow-up, and balanced between the 
schedules (table 3). There were no cases of brachial 
plexopathy in the 82 women given 40 Gy in 15 fractions 
or in the 79 women given 50 Gy in 25 fractions to the 
supraclavicular fossa, axilla, or both. An unusually 
marked acute reaction during radiotherapy was recorded 
for 16 (0·7%) patients (13 after 50 Gy [1·2%], three after 
40 Gy [0·3%]). Of these, 14 cases were severe skin 
reactions (extensive moist desquamation), one was an 
infected seroma in the scar area, and one had severe pain 
in the breast tissue and ribs. 
There were 36 (1·6%) contralateral breast cancers 
(19 after 50 Gy (1·7%), 17 after 40 Gy [1·5%]), and 
58 patients [2·6%] had other second primary cancers 
(32 after 50 Gy [2·9%], 26 after 40 Gy [2·3%]), the most 
frequent being lung (ten), endometrial (ten), ovarian 
(eight), and colon (ﬁ ve). The remaining 25 incidences of 
second primary cancers consisted of one or two cases of 
several diﬀ erent types.
Discussion
START trial B aimed to provide a robust evidence base 
for clinical practice in breast radiotherapy by comparing 
50 Gy (122/1105)
40 Gy (87/1110)
0
10
20
30
40
50
60
70
80
90
100
Pe
rc
en
ta
ge
 o
f p
at
ie
nt
s w
ith
 n
o
di
st
an
t r
el
ap
se
0 1 2 3 4 5 6
Number at risk
50 Gy
40 Gy
1105
1110
1069
1083
1027
1052
973
1011
925
962
780
803
435
449
A
B
0·05
0·10
0·15
0
Cu
m
ul
at
iv
e 
ha
za
rd
 ra
te
Years since randomisation
0 1 2 3 4 5 6
Figure 3: Kaplan-Meier plot (A) and Nelson-Aalen cumulative hazard plot (B) of distant relapse in 
2215 patients
0 1 2 3 4 5
0
10
20
30
40
50
60
70
80
90
100
Pe
rc
en
ta
ge
 o
f p
at
ie
nt
s w
ith
 n
o 
ch
an
ge
 in
 b
re
as
t a
pp
ea
ra
nc
e
50 Gy (167/461)
40 Gy (145/462)
Number at risk
50 Gy
41·6 Gy
461
462
457
458
241
271
Years since randomisation
Figure 4: Kaplan-Meier plot of mild/marked change in breast appearance (photographic) in 923 patients with 
breast conserving surgery
Articles
1104 www.thelancet.com   Vol 371   March 29, 2008
a commonly used 15-fraction schedule with the 
international standard based on 25 fractions of 2·0 Gy. 
The analysis of change in breast appearance 
(photographic) suggests that 40 Gy in 15 fractions over 
3 weeks causes slightly less permanent damage to 
normal breast tissues than a standard regimen of 50 Gy 
in 25 fractions over 5 weeks. This observation is 
consistent with results of the RMH/GOC pilot trial35 and 
the START Trial A,21 which suggest that 40 Gy in 
15 fractions over 3 weeks is equivalent in terms of late 
normal tissue eﬀ ects in the breast to a total dose of 46 Gy 
delivered in 2·0 Gy fractions.21,37 The patient quality of 
life self-assessments of normal tissue eﬀ ects in START 
Trial B are also consistent with this relation, suggesting 
5-year estimates in favour of the 40 Gy group in most of 
the assessed normal tissue eﬀ ects.
A preliminary analysis of the concordance of 
assessments of the normal tissue eﬀ ects by patients, 
photographs, and physicians shows that in general 
patients tend to score eﬀ ects more severely. A full 
description of patient-rated cosmesis and quality of life 
will be reported separately.
Physician assessments of normal tissue eﬀ ects have 
not been presented in this paper. Preliminary analysis of 
these data produces estimates of the relative eﬀ ects of the 
fractionation schedules, which are similar to those 
assessed by the photographic and patient self-assessments. 
Some variation existed, however, between centres in the 
practice used to complete the yearly case report forms. 
Most centres completed these forms in the presence of 
the patient, whereas others completed them afterwards 
from hospital case notes. Since the level of detail included 
in the hospital case notes varied within and between 
centres, this practice, although unbiased between 
treatment groups, could have led to underreporting of 
physician-assessed normal tissue eﬀ ects. The results of 
the physician assessments will thus be the subject of a 
separate manuscript, reporting also the sensitivity of the 
endpoints according to method of completion of the 
forms.
A median follow-up of 5 years is too short to allow 
assessment of all the potential late normal tissue eﬀ ects 
such as cardiac damage. Follow-up of all women within 
the trial is continuing in order to assess the long-term 
eﬀ ects of the fractionation schedules. However, the 
RMH/GOC pilot data with a median of 10 years’ follow-up 
showed that although estimates of absolute rates of 
normal tissue eﬀ ects change with time, the relative 
eﬀ ects of diﬀ erent fractionation schedules remain 
unchanged.37 15–20 years of follow-up will be needed to 
reliably measure cardiac eﬀ ects. The short-term priority 
is to protect the heart from exposure to radiotherapy; 
something that is now possible with advanced 
radiotherapy technologies.
The local-regional relapse rate was lower than 
originally anticipated. A 5-year local-regional relapse 
rate of 10% in the 50 Gy group was originally assumed, 
on the basis of data from the pilot trial initiated in 1986. 
Since then, risks of local and metastatic breast cancer 
relapse have fallen because of improvements in the 
0·5 0·6 0·7 0·8 0·9
Hazard ratio (95% CI)
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Change in breast appearance (photographic)*
Kaplan-Meier 5 year event rate
(95% CI), %
Hazard ratio
(95% CI)
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Figure 5: Forest plot of late normal tissue eﬀ ects assessed as moderate/marked by patients and mild/marked from photographs
Fractionation schedule Total n=2215
50 Gy 
n=1105
40 Gy 
n=1110
Ischaemic heart disease*
Reported 19 (1·7) 15 (1·3) 34 (1·5)
Conﬁ rmed† [left-sided]‡ 12 (1·1) [4] 7 (0·6) [3] 19 (0·9) [7]
Symptomatic rib fracture§
Reported 17 (1·5) 16 (1·4) 33 (1·5)
Conﬁ rmed† 2 (0·2) 2 (0·2) 4 (0·2)
Symptomatic lung ﬁ brosis
Reported 15 (1·4) 16 (1·4) 31 (1·4)
Conﬁ rmed† 1 (0·1) 3 (0·3) 4 (0·2)
Data are n (%) unless otherwise stated. *11 patients had pre-existing heart disease 
at randomisation and were excluded. †Cases conﬁ rmed following imaging and 
further investigations. ‡Conﬁ rmed cases of ischaemic heart disease in patients 
with left-sided primary tumours. §Reported cases include four with rib fracture 
after bone metastases and three after trauma.
Table 3: Incidence of ischaemic heart disease, symptomatic rib fracture, 
and symptomatic lung ﬁ brosis according to fractionation schedule
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treatment and management of breast cancer patients. 
While accrual was still continuing, the emerging data 
presented in conﬁ dence to the Independent Data 
Monitoring Committee suggested that relapse rates 
were likely to be lower than predicted. At that time, 
adhering to appropriate governance procedures, the 
potential eﬀ ects of the predicted lower than expected 
relapse rates were discussed by the independent Trial 
Steering Committee and the Independent Data 
Monitoring Committee. The consensus from these 
independent advisory committees was that there was no 
strong scientiﬁ c rationale for changing the protocols 
and increasing the sample size. 
Since the local-regional relapse rate was lower than 
expected (<4%), the study actually has greater power 
than originally planned to exclude a 5% absolute 
diﬀ erence (99% power, assuming 4% in control group), 
since this represents a much larger relative treatment 
eﬀ ect (4% in control group vs 9% in test group compared 
with 10% vs 15% as speciﬁ ed in the protocol). 
Alternatively, with the lower baseline local-regional 
relapse rate the same sample size provides suﬃ  cient 
power to exclude smaller absolute diﬀ erences. For 
example with a 4% local-regional relapse rate in the 
control group, the study is able to exclude an absolute 
increase of 3·5% with a similar level (97%) of power as 
originally planned. The eﬀ ect of 40 Gy in 15 fractions is 
unlikely to be worse than 50 Gy in 25 fractions. 
In view of the hazard ratio for local-regional relapse 
of 0·79 (95% CI 0·48 to 1·29), the absolute diﬀ erence in 
5-year local-regional relapse rate suggests a beneﬁ t after 
40 Gy corresponding to six fewer local-regional relapses 
per 1000 women. The 95% CI for the absolute diﬀ erence 
indicates that the test schedule could prevent, at best, 
up to 17 relapses, or cause, at worst, an additional nine 
relapses per 1000 women. The apparent diﬀ erences in 
disease-free and overall survival between treatment 
groups are unexpected. Such diﬀ erences are unlikely to 
be due to diﬀ erences in local tumour control between 
treatment groups, since these are too small and would 
translate into survival gains after 15 years,38 not at the 
early timepoint where the apparent divergence in distant 
metastasis rates is seen. Similarly, they are unlikely to 
be due to diﬀ erences in the baseline characteristics or 
adjuvant therapy, since these were well-balanced 
between the treatment groups. 
Data for oestrogen receptor status were not obtained 
as part of the trial, but routine policy in most of the 
centres during the accrual period was to prescribe 
tamoxifen only to oestrogen receptor-positive patients 
or those whose oestrogen receptor status was unknown. 
Hence tamoxifen use is a reasonable surrogate for 
oestrogen receptor status in the trial, which was balanced 
between the treatment groups. There are many factors 
which aﬀ ect relapse and survival, including others 
which were unknown in the trial such as HER2 status; 
the purpose of randomisation is to ensure a balance in 
the unknown as well as the known prognostic factors. 
We cannot ascribe the survival diﬀ erence to any 
biological or treatment-related factor, and can only 
conclude that this diﬀ erence might be due to chance 
and could diminish with further follow-up. Long-term 
follow-up of these women is continuing, to verify 
whether the relative eﬀ ects of the schedules remain 
stable over time, in terms of late normal tissue eﬀ ects as 
well as relapse and survival.
The only other large trial with which START Trial B can 
be compared is a Canadian trial15 that tested 42·5 Gy in 
16 fractions of 2·6 Gy fractions over 22 days against 50 Gy 
in 25 fractions over 35 days in 1234 women after tumour 
excision for early breast cancer. The 5-year local relapse 
rates were 2·8% after the shorter schedule and 3·2% after 
the standard 5-week regimen (absolute diﬀ erence 0·4%, 
95% CI –1·5 to 2·4%). The proportion of patients with 
clinically assessed excellent or good global cosmetic 
outcome was also similar between groups (absolute 
diﬀ erence –0·6%, 95% CI –6·5 to 5·5%). The similarity 
of normal tissue eﬀ ects is consistent with the results of 
START Trial B. On the same assumptions applied above, 
42·5 Gy in 16 fractions is equivalent to 50 Gy in 
25 fractions in terms of late-onset normal tissue eﬀ ects 
in the breast and chest wall. Reliable comparison of 
tumour control is limited by the small number of relapses 
in both the Canadian study (44 events) and in START 
Trial B (65 events).
In conclusion, after surgery for early breast cancer, a 
radiotherapy schedule delivering 40 Gy in 15 fractions 
over 3 weeks seems to oﬀ er local regional tumour control 
and rates of late normal tissue eﬀ ects at least as good as 
the accepted international standard of 50 Gy in 
25 fractions over 5 weeks.
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